OOIR: Observatory of International Research

Papers

(The H4-Index of Lung Cancer is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer	136
Clinical utility of comprehensive genomic profiling in non-small cell lung cancer: An analysis of a nation-wide database	93
Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial	77
A whole-slide image (WSI)-based immunohistochemical feature prediction system improves the subtyping of lung cancer	71
Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen	70
Role of 18F-FDG PET/CT in the postoperative follow-up in patients with stage I-III NSCLC: A retrospective single-institution study	60
Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report	57
Functional resilience and overall survival in adults treated for advanced non-small-cell lung cancer	56
1000 Robotic-assisted lobectomies for primary lung cancer: 16 years single center experience	53
Impact of genetic status on the survival outcomes of patients with clinical stage I non-small cell lung cancer with a radiological pure-solid appearance	52
EpCAM-positive disseminated cancer cells in bone marrow impact on survival of early-stage NSCLC patients	50
Imaging in pleural mesothelioma: A review of the 15th International Conference of the International Mesothelioma Interest Group	48
Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy	45
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide	44
Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions	43
The Scottish Mesothelioma Network: impact of a national multidisciplinary team on overall survival in malignant pleural mesothelioma	43
The impact of osimertinib’ line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance	42
Combination of calretinin, MALAT1, and GAS5 as a potential prognostic biomarker to predict disease progression in surgically treated mesothelioma patients	40
Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis	40
ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis	39
The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) p	37
Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trial	37
Neuroendocrine transformation from EGFR/ALK-wild type or TKI-naïve non-small cell lung cancer: An under-recognized phenomenon	36
Radiological precursor lesions of lung squamous cell carcinoma: Early progression patterns and divergent volume doubling time between hilar and peripheral zones	36
Clinical implementation of value based healthcare: Impact on outcomes for lung cancer patients	35

CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials	35
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer	35
Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis	34
Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction	34
66 Early Experiences of the Use of Combination Immunotherapy for the Treatment of Malignant Mesothelioma from 2022–2023 – Real-World Evidence of 1-Year Data from a Single UK Tertiary Cancer Centre	34
149 Stereotactic radiosurgery (SRS) for the treatment of brain metastases: Outcomes for lung cancer patients in South Wales	33
84 National Real World Study of Adjuvant Osimertinib in Resected EGFR Mutated Lung Cancer	33
190 Decision Making for Thoracic Radiotherapy and Prophylactic Cranial Irradiation in ES-SCLC Post Chemoimmunotherapy	33